Correlation Between Blueprint Medicines and United Therapeutics
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and United Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and United Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and United Therapeutics, you can compare the effects of market volatilities on Blueprint Medicines and United Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of United Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and United Therapeutics.
Diversification Opportunities for Blueprint Medicines and United Therapeutics
0.51 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Blueprint and United is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and United Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on United Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with United Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of United Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and United Therapeutics go up and down completely randomly.
Pair Corralation between Blueprint Medicines and United Therapeutics
Given the investment horizon of 90 days Blueprint Medicines Corp is expected to generate 1.57 times more return on investment than United Therapeutics. However, Blueprint Medicines is 1.57 times more volatile than United Therapeutics. It trades about 0.03 of its potential returns per unit of risk. United Therapeutics is currently generating about -0.1 per unit of risk. If you would invest 8,682 in Blueprint Medicines Corp on December 30, 2024 and sell it today you would earn a total of 190.00 from holding Blueprint Medicines Corp or generate 2.19% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Blueprint Medicines Corp vs. United Therapeutics
Performance |
Timeline |
Blueprint Medicines Corp |
United Therapeutics |
Blueprint Medicines and United Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Blueprint Medicines and United Therapeutics
The main advantage of trading using opposite Blueprint Medicines and United Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, United Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will offset losses from the drop in United Therapeutics' long position.Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
United Therapeutics vs. Incyte | United Therapeutics vs. Alnylam Pharmaceuticals | United Therapeutics vs. Ultragenyx | United Therapeutics vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Complementary Tools
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |